The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors show efficacy in homologous recombination (HR)-deficient cancers.
• PARP inhibitors also demonstrate potential in HR-competent cancers by amplifying DNA damage and inducing immunogenic cell death.
• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but benefit only a subset of patients.

Purpose of the Study:

• To review the mechanisms and immune roles of PARP inhibitors.
• To discuss the rationale for combining PARP inhibitors with ICIs.
• To summarize clinical studies evaluating this combination therapy.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of mechanisms by which PARP inhibitors modulate the tumor immune microenvironment.
• Synthesis of data on the efficacy and safety of PARP inhibitor and ICI combinations.

Main Results:

• PARP inhibitors increase tumor neoantigens, upregulate interferons and PD-L1, and modulate the tumor microenvironment.
• These effects enhance the potential for a stronger antitumor immune response.
• Combination therapy with PARP inhibitors and ICIs shows promise in overcoming resistance to ICI monotherapy.

Conclusions:

• PARP inhibitors can potentiate the therapeutic effects of ICIs.
• The combination of PARP inhibitors and ICIs represents a viable therapeutic strategy for various malignancies.
• Further clinical investigation is warranted to optimize this combined regimen.